Published in J Stroke Cerebrovasc Dis on November 01, 2000
Engineered polymers for advanced drug delivery. Eur J Pharm Biopharm (2008) 1.17
Therapeutic time window and dose dependence of xenon delivered via echogenic liposomes for neuroprotection in stroke. CNS Neurosci Ther (2013) 0.79
White-coat hypertension as a cause of cardiovascular dysfunction. Lancet (1996) 4.68
Termination of trial of streptokinase in severe acute ischaemic stroke. MAST Study Group. Lancet (1995) 4.50
Is hyperglycaemia an independent predictor of poor outcome after acute stroke? Results of a long-term follow up study. BMJ (1997) 3.88
Anticardiolipin antibodies in an unselected stroke population. Lancet (1994) 3.66
Interatrial septal abnormalities and stroke: a meta-analysis of case-control studies. Neurology (2000) 3.64
Influence of cholesterol on survival after stroke: retrospective study. BMJ (1997) 3.64
Poor accuracy of stroke scoring systems for differential clinical diagnosis of intracranial haemorrhage and infarction. Lancet (1994) 3.03
Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet (2004) 2.51
Thrombolysis outcomes in acute ischemic stroke patients with prior stroke and diabetes mellitus. Neurology (2011) 2.24
Pneumonia and urinary tract infection after acute ischaemic stroke: a tertiary analysis of the GAIN International trial. Eur J Neurol (2004) 2.12
Comparison of neurological scales and scoring systems for acute stroke prognosis. Stroke (1996) 1.83
The initial attack of acute rheumatic fever during childhood in North India; a prospective study of the clinical profile. Circulation (1974) 1.65
Selfotel in acute ischemic stroke : possible neurotoxic effects of an NMDA antagonist. Stroke (2000) 1.47
Functional outcome measures in contemporary stroke trials. Int J Stroke (2009) 1.43
C-reactive protein and outcome after ischemic stroke. Stroke (1999) 1.42
Effect of a gonadotropin releasing hormone analog on cerebral hemodynamics in premenopausal women. Climacteric (2005) 1.38
iNOS and nitrotyrosine expression after spinal cord injury. J Neurotrauma (2001) 1.33
Clinical experience with excitatory amino acid antagonist drugs. Stroke (1995) 1.33
Randomized trial of graded compression stockings for prevention of deep-vein thrombosis after acute stroke. QJM (2000) 1.27
Amyloid-beta peptides are cytotoxic to oligodendrocytes. J Neurosci (2001) 1.23
A randomised, controlled pilot study to investigate the potential benefit of intervention with insulin in hyperglycaemic acute ischaemic stroke patients. Cerebrovasc Dis (2006) 1.15
A new conception of coronary artery preponderance. Acta Anat (Basel) (1972) 1.13
Hemorrhagic transformation in acute ischemic stroke. The MAST-E study. MAST-E Group. Stroke (1999) 1.12
Corticotropin-releasing factor induces a place aversion independent of its neuroendocrine role. Brain Res (1992) 1.08
Microinjections of an opiate receptor antagonist into the bed nucleus of the stria terminalis suppress heroin self-administration in dependent rats. Brain Res (2000) 1.08
The experiences of an acute stroke unit--implications for multicentre acute stroke trials. J Neurol Neurosurg Psychiatry (1993) 1.06
Effects of angiotensin converting enzyme inhibitor, perindopril, on autonomic reflexes. Eur J Clin Pharmacol (1986) 1.05
Peroneal stimulator; evaluation for the correction of spastic drop foot in hemiplegia. Arch Phys Med Rehabil (1996) 1.03
Mistyping of the human angiotensin-converting enzyme gene polymorphism: frequency, causes and possible methods to avoid errors in typing. J Mol Endocrinol (1996) 1.03
The prognostic value of the components of the Glasgow Coma Scale following acute stroke. QJM (2003) 1.03
The apolipoprotein E epsilon4 allele and outcome in cerebrovascular disease. Stroke (1998) 1.03
Glucocorticoid receptor-mediated suppression of activator protein-1 activation and matrix metalloproteinase expression after spinal cord injury. J Neurosci (2001) 1.02
Haemodynamic and humoral effects of oral perindopril, an angiotensin converting enzyme inhibitor, in man. Br J Clin Pharmacol (1987) 1.02
Effect of apolipoprotein E genotype on in-hospital mortality following intracerebral haemorrhage. Acta Neurol Scand (2003) 1.00
Dose optimization of intravenous magnesium sulfate after acute stroke. Stroke (1998) 1.00
Amyloid beta peptide-induced cerebral endothelial cell death involves mitochondrial dysfunction and caspase activation. J Cereb Blood Flow Metab (2001) 1.00
Differences in first dose response to angiotensin converting enzyme inhibition in congestive heart failure: a placebo controlled study. Br Heart J (1991) 1.00
Termination of Acute Stroke Studies Involving Selfotel Treatment. ASSIST Steering Committed. Lancet (1997) 0.99
Cultural influences on delusion. Psychiatr Clin (Basel) (1978) 0.99
A recognition tool for transient ischaemic attack. QJM (2008) 0.99
Extraction and phytochemical investigation of Calotropis procera: effect of plant extracts on the activity of diverse muscles. Pharm Biol (2010) 0.98
Conditioning and opiate withdrawal. Nature (2000) 0.98
Statin administration prior to ischaemic stroke onset and survival: exploratory evidence from matched treatment-control study. Eur J Neurol (2005) 0.97
Effects of intravenous S-9780, an angiotensin-converting enzyme inhibitor, in normotensive subjects. J Cardiovasc Pharmacol (1987) 0.97
The haemodynamic and humoral effects of treatment for one month with the angiotensin converting enzyme inhibitor perindopril in salt replete hypertensive patients. Eur J Clin Pharmacol (1987) 0.97
Differentiation between gaseous and formed embolic materials in vivo. Application in prosthetic heart valve patients. Stroke (1994) 0.97
Age and the pharmacokinetics and pharmacodynamics of chronic enalapril treatment. Clin Pharmacol Ther (1987) 0.95
Oxygen-glucose deprivation induces inducible nitric oxide synthase and nitrotyrosine expression in cerebral endothelial cells. Stroke (2000) 0.94
Excitatory amino acid antagonists for acute stroke. Cochrane Database Syst Rev (2003) 0.94
The AMPA antagonist ZK 200775 in patients with acute ischaemic stroke: a double-blind, multicentre, placebo-controlled safety and tolerability study. Cerebrovasc Dis (2005) 0.93
Double blind controlled study of low dose intravenous perindoprilat or enalaprilat infusion in elderly patients with heart failure. Br Heart J (1993) 0.93
Tissue and plasma angiotensin converting enzyme and the response to ACE inhibitor drugs. Br J Clin Pharmacol (1991) 0.93
A randomized, double-blind, placebo-controlled pilot trial of intravenous magnesium sulfate in acute stroke. Stroke (1995) 0.92
Transhemispheric passage of microemboli in patients with unilateral internal carotid artery occlusion. Stroke (1993) 0.92
Duration of neuroprotective treatment for ischemic stroke. Stroke (1998) 0.91
Perindopril. A review of its pharmacokinetics and clinical pharmacology. Drugs (1990) 0.91
Susceptibility to cerebral infarction in the stroke-prone spontaneously hypertensive rat is inherited as a dominant trait. Stroke (1998) 0.90
Overnight clonidine suppression test in the diagnosis and exclusion of pheochromocytoma. Am J Med (1988) 0.90
Streptokinase in acute ischemic stroke: an individual patient data meta-analysis : The Thrombolysis in Acute Stroke Pooling Project. Stroke (2000) 0.88
Prevention of shoulder subluxation after stroke with electrical stimulation. Stroke (1999) 0.88
ABC of arterial and venous disease. Acute stroke. BMJ (2000) 0.88
Transcranial Doppler ultrasound in commercial air divers: a field study including cases with right-to-left shunting. Undersea Hyperb Med (1995) 0.87
Epidemiological aspects of referral to TIA clinics in Glasgow. Scott Med J (2007) 0.87
Transcranial Doppler detection of microemboli in prosthetic heart valve patients: dependency upon valve type. Eur J Cardiothorac Surg (1996) 0.87
Lack of association between angiotensin converting enzyme gene insertion/deletion polymorphism and stroke. J Hypertens (1995) 0.86
Chronic cyanide exposure: a clinical, radioisotope, and laboratory study. Br J Ind Med (1975) 0.86
Blunted response to systemic nitric oxide synthase inhibition in the cerebral circulation of patients with Type 2 diabetes. Diabet Med (2006) 0.86
Angiotensin-converting enzyme inhibitors in the elderly. Am Heart J (1989) 0.86
Intravenous thrombolysis for acute ischaemic stroke: preliminary experience with recombinant tissue plasminogen activator in the UK. Cerebrovasc Dis (2005) 0.86
Effect of perindopril on cerebral and renal perfusion in stroke patients with carotid disease. Stroke (2001) 0.85
Early clinical experience with the novel proteasome inhibitor PS-519. Br J Clin Pharmacol (2002) 0.85
On the origin of cerebrovascular microemboli associated with prosthetic heart valves. Neurol Res (1995) 0.84
Interdependence of stroke outcome scales: reliable estimates from the Virtual International Stroke Trials Archive (VISTA). Int J Stroke (2013) 0.84
The ABCD and ABCD2 as predictors of stroke in transient ischemic attack clinic outpatients: a retrospective cohort study over 14 years. QJM (2010) 0.84
Hyperglycaemia in acute stroke--to treat or not to treat. Cerebrovasc Dis (2009) 0.84
Safety and tolerability study of aptiganel hydrochloride in patients with an acute ischemic stroke. Stroke (1999) 0.84
Does the cognitive measure Cog-4 show improvement among patients treated with thrombolysis after acute stroke? Int J Stroke (2012) 0.84
The association of post-stroke neurological improvement with risk of subsequent deterioration due to stroke events. Eur J Neurol (2007) 0.83
Detection of microemboli by transcranial Doppler ultrasound. Tex Heart Inst J (1996) 0.83
Pharmacological effects of the non-competitive NMDA antagonist CNS 1102 in normal volunteers. Br J Clin Pharmacol (1994) 0.82
A body-worn gait analysis system for evaluating hemiplegic gait. Med Eng Phys (1995) 0.82
Haemodynamic response and pharmacokinetics after the first dose of quinapril in patients with congestive heart failure. Br J Clin Pharmacol (1994) 0.82
Prevalence and characteristics of intracranial microemboli signals in patients with different types of prosthetic cardiac valves. Stroke (1994) 0.82
Quantification of ultrasound emboli signals in patients with cardiac and carotid disease. Stroke (1993) 0.82
Apolipoprotein E genotype, coagulation, and survival following acute stroke. Neurology (2001) 0.82
Morphological and radiometrical study of the human intervertebral foramina of the cervical spine. Folia Morphol (Warsz) (2014) 0.81
Chronic morphine treatment alters NMDA receptor-mediated synaptic transmission in the nucleus accumbens. J Neurosci (1999) 0.81
Doppler emboli signals vary according to stroke subtype. Stroke (1994) 0.81
The pharmacokinetics and pharmacodynamics of perindopril in patients with hepatic cirrhosis. Br J Clin Pharmacol (1989) 0.81
A non-invasive gating device for continuous drug delivery that allows control over the timing and duration of spontaneous opiate withdrawal. J Neurosci Methods (2004) 0.81
The effect of HRT on cerebral haemodynamics and cerebral vasomotor reactivity in post-menopausal women. Hum Reprod (2004) 0.81
Natural history of complications after intracerebral haemorrhage. Eur J Neurol (2009) 0.81
The comparative anatomy of the blood supply of cardiac ventricles in the albino rat and guinea-pig. J Anat (1978) 0.81
Coagulation activity and emboli counts in patients with prosthetic cardiac valves. Stroke (1994) 0.80
The response to the first dose of an angiotensin converting enzyme inhibitor in uncomplicated hypertension--a placebo controlled study utilising ambulatory blood pressure recording. Br J Clin Pharmacol (1991) 0.80
Study of methyl transferase (G9aMT) and methylated histone (H3-K9) expressions in unexplained recurrent spontaneous abortion (URSA) and normal early pregnancy. Mol Hum Reprod (2011) 0.80
Circulating growth hormone, insulin-like growth factor I, cortisol and free thyroxine in children with schistosomiasis with and without hepatic fibrosis. J Trop Pediatr (1991) 0.80
Studies with low dose intravenous diacid ACE inhibitor (perindoprilat) infusions in normotensive male volunteers. Br J Clin Pharmacol (1992) 0.80
Angiotensin-converting enzyme inhibitors in heart failure: blood pressure changes after the first dose. Am Heart J (1993) 0.79